SAN FRANCISCO, Nov. 27, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that its corporate presentation
The presentation will be accessible via a Webcast through a link posted on the Investors,
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
InvestorsJennifer Ruddock of Nektar Therapeutics415-482-5585
View original content:http://www.prnewswire.com/news-releases/nektar-to-webcast-presentation-at-the-piper-jaffray-29th-annual-healthcare-conference-in-new-york-city-300562135.html
SOURCE Nektar Therapeutics
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All